A new compound, discovered jointly by international pharmaceutical company Servier, headquartered in France, and Vernalis (R&D), a company based in the UK, has been shown by researchers at the Walter and Eliza Hall Institute and Servier to block a protein that is essential for the sustained growth of up to a quarter of all cancers.
The research presents a new way to efficiently kill these cancerous cells and holds promise for the treatment of blood cancers such as acute myeloid leukaemia,lymphoma and multiple myeloma, as well as solid cancers such as melanoma and cancers of the lung and breast. It is published online today in the journal Nature.
The Servier compound – S63845 – targets a protein of the BCL2 family, called MCL1, which is essential for the sustained survival of these cancer cells.
Institute scientist Associate Professor Guillaume Lessene, who led the Walter and Eliza Hall Institute’s research team in Melbourne, Australia, said the work provided the first clear preclinical evidence that inhibiting MCL1 was effective in targeting several cancer types.
“MCL1 is important for many cancers because it is a pro-survival protein that allows the cancerous cells to evade the process of programmed cell death that normally removes cancer cells from the body,” Associate Professor Lessene said. “Extensive studies performed in a variety of cancer models have shown that S63845 potently targets cancer cells dependent on MCL1 for their survival.”
The institute team of Associate Professor Lessene worked with haematologist Associate Professor Andrew Wei and Dr Donia Moujalled from The Alfred Hospital and Servier scientists, to demonstrate that not only was S63845 effective against several cancer types, but that it could also be delivered at doses that were well tolerated by normal cells.
Dr Olivier Geneste, Director of Oncology Research at Servier, said this preclinical research represented major findings regarding the druggability of MCL1, a valuable and highly challenging target. “S63845 was discovered through collaboration with the fragment and structure based discovery expertise at Vernalis,” he said. “As part of the ongoing Servier / Novartis collaboration on this target class, clinical development of a MCL1 inhibitor should be launched in the near future.”
Associate Professor Lessene said the research provided further evidence of the usefulness of a new class of anti-cancer drugs called BH3 mimetics. “BH3 mimetics inhibit a group of proteins known as the ‘pro-survival BCL-2 proteins’,” he said. “MCL1 is a member of this protein family, and inhibiting it activates the process of programmed cell death. Walter and Eliza Hall Institute researchers revealed the role of BCL-2 in cancer more than 28 years ago and the essential role of MCL1 for the survival of malignant cells four years ago.”
The Latest on: Cancer treatment
via Google News
The Latest on: Cancer treatment
- NCI gives $8.7 million grant to UCLA prostate cancer programon December 1, 2019 at 5:24 am
... 8.7 million grant to the prostate cancer program at UCLA Jonsson Comprehensive Cancer Center and UCLA Health. The money — funded through the Specialized Program of Research Excellence (SPORE) — ...
- Ask Amy: Woman in treatment refuses to be 'the sick girl'on December 1, 2019 at 3:16 am
Treatment is ongoing, and although she gets tired, she's hanging in there, with the help of her business partner. Every unexpected issue destroys her. She is a very ordered person who has a problem ...
- Exploring why comprehensive care can make a big difference in cancer treatmenton November 30, 2019 at 9:06 pm
patients should ask about the expertise of both the physicians and the facility for their cancer type before initiating treatment. 2. Team care When a multidisciplinary team of surgeons, medical ...
- Cancer survivors report an information gap in treatment side effectson November 30, 2019 at 12:08 am
Cancer treatments can save lives, but they also often cause a range of side effects. A recent patient survey in the United States has revealed how people feel about these effects and the information ...
- Japan Approves Genetic Testing For Breast Cancer Treatmenton November 29, 2019 at 8:12 am
This month, Japan’s Ministry of Health, Labour and Welfare approved the BRACAnalysis® Diagnostic System, also known as the “BRACAnalysis” genetic test, to be used to test which breast cancer patients ...
- Risk of dementia following androgen deprivation therapy for treatment of prostate canceron November 29, 2019 at 4:46 am
Evidence for androgen deprivation therapy (ADT) and risk of dementia is both limited and mixed. We aimed to assess the association between ADT and risk of dementia among men with localized and locally ...
- A Small Number Of Men With Prostate Cancer Are ‘Super Responders’ To Immunotherapyon November 28, 2019 at 4:03 pm
Results from a new clinical trial have shown that some men with advanced prostate cancer can live for at least two more years on immunotherapy after exhausting all other treatment options. The work ...
- Bevacizumab for the treatment of non-small cell lung cancer patients with synchronous brain metastaseson November 28, 2019 at 2:18 am
Bevacizumab is FDA-approved in the treatment of primary brain tumors, but its efficacy in patients with brain metastases could be better-studied. This study examines a population of non-small cell ...
- Bone Cancer Treatment Market Growth, Size, Opportunity & Industry Analysis, 2018-2026on November 27, 2019 at 9:26 pm
The bone cancer treatment market is analyzed on the basis of type of bone cancer into primary bone cancer and secondary bone cancer. Primary bone cancer originates from fast and uncontrollable growth ...
via Bing News